Business
INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans
First patient treated in Phase II portion of clinical trial in metastatic prostate cancer at the West Los Angeles Veterans Administration Hospital Boca Raton,
About this update from Inmune Bio Inc.
[{"type":"text","content":"First patient treated in Phase II portion of clinical trial in metastatic prostate cancer at the West Los Angeles Veterans Administration Hospital Boca Raton, Florida, Jan. 28, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, has an ongoing Phase I/II trial in men with metastatic castration-resistant prostate cancer (mCRPC). The Company is pleased to announce the participation of a patient at the West Los Angeles VA Medical Center in the trial. The participant received the investigational intervention, as an out-patient per the protocol, under the care of Matthew Rettig, MD., Chief, Hematology-Oncology, VA Greater Los Angeles Healthcare System, Professor of Medicine and Urology, Medical Director Prostate Cancer Program, David Geffen School of Medicine and the Jonsson Comprehensive Cancer Center at the UCLA. The VA Health Care System provides medical care to the Veterans of the US military. Every year, approximately 15,000 Veterans are diagnosed and treated at the VA for prostate cancer and over 200,000 Veterans are prostate cancer survivors. Under Rettig’s leadership, 900 patients with prostate cancer have participated in over two dozen clinical trials at the West LA VA Medical Center. The Care PC trial is the first using a NK targeted biologic therapy. The Veteran received the “medium” dose of INKmune initiating the Phase II portion of the trial. “The INmune Bio study represents a new immune therapy approach to treating advanced prostate cancer. The study involves the use of cellular therapy treatment that activates NK cells, which are immune cells known to target tumor cells and are in relative abundance in prostate cancer,” said Rettig, Principal Investigator, about the the CarePC program. “Unlike most immunotherapies, this study involves treatment that is given as an outpatient and appears to have minimal side effects, which helps the management of prostate cancer among Veterans and the US population at large.” In 2022, Congress signed into law the Joseph Maxwell Cleland and Robert Joseph Dole Memorial Veterans Benefits and Health Care Improvement Act of 2022, also known as the Cleland-Dole Act. In response to the Cleland-Dole Act, which requires VA t...